Thompson Rubinstein Investment Management Inc. OR held its stake in shares of CVS Health Corporation (NYSE:CVS) during the third quarter, Holdings Channel reports. The firm owned 23,222 shares of the pharmacy operator’s stock at the end of the third quarter. Thompson Rubinstein Investment Management Inc. OR’s holdings in CVS Health Corporation were worth $2,067,000 at the end of the most recent reporting period.

Other large investors have also modified their holdings of the company. Springbok Capital Management LLC boosted its position in shares of CVS Health Corporation by 190.5% in the first quarter. Springbok Capital Management LLC now owns 1,130 shares of the pharmacy operator’s stock valued at $117,000 after buying an additional 741 shares during the last quarter. SevenBridge Financial Group LLC purchased a new position in shares of CVS Health Corporation during the first quarter valued at about $575,000. BNP Paribas Arbitrage SA boosted its position in shares of CVS Health Corporation by 18.5% in the second quarter. BNP Paribas Arbitrage SA now owns 352,871 shares of the pharmacy operator’s stock valued at $33,784,000 after buying an additional 55,145 shares during the last quarter. M. Kraus & Co boosted its position in shares of CVS Health Corporation by 2.2% in the second quarter. M. Kraus & Co now owns 37,114 shares of the pharmacy operator’s stock valued at $3,553,000 after buying an additional 800 shares during the last quarter. Finally, Fulton Bank N.A. boosted its position in shares of CVS Health Corporation by 9.4% in the second quarter. Fulton Bank N.A. now owns 28,840 shares of the pharmacy operator’s stock valued at $2,761,000 after buying an additional 2,478 shares during the last quarter. 80.44% of the stock is owned by institutional investors and hedge funds.

Institutional Ownership by Quarter for CVS Health Corporation (NYSE:CVS)

CVS Health Corporation (NYSE:CVS) traded up 1.47% during midday trading on Tuesday, reaching $75.88. The company’s stock had a trading volume of 8,649,575 shares. The company has a 50 day moving average price of $81.31 and a 200 day moving average price of $91.35. The firm has a market cap of $80.92 billion, a price-to-earnings ratio of 16.26 and a beta of 0.88. CVS Health Corporation has a 1-year low of $69.30 and a 1-year high of $106.67.

CVS Health Corporation (NYSE:CVS) last issued its earnings results on Tuesday, November 8th. The pharmacy operator reported $1.64 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $1.57 by $0.07. The business earned $44.60 billion during the quarter, compared to the consensus estimate of $45.29 billion. CVS Health Corporation had a return on equity of 17.18% and a net margin of 2.96%. The company’s revenue for the quarter was up 15.5% on a year-over-year basis. During the same period in the prior year, the business posted $1.28 EPS. On average, equities research analysts expect that CVS Health Corporation will post $5.81 EPS for the current year.

The firm also recently announced a quarterly dividend, which was paid on Thursday, November 3rd. Stockholders of record on Monday, October 24th were paid a dividend of $0.425 per share. This represents a $1.70 dividend on an annualized basis and a dividend yield of 2.24%. The ex-dividend date of this dividend was Thursday, October 20th. CVS Health Corporation’s dividend payout ratio (DPR) is 36.40%.

ILLEGAL ACTIVITY NOTICE: “Thompson Rubinstein Investment Management Inc. OR Maintains Position in CVS Health Corporation (CVS)” was first posted by Daily Political and is owned by of Daily Political. If you are accessing this report on another site, it was stolen and republished in violation of US and international copyright & trademark legislation. The original version of this report can be read at http://www.dailypolitical.com/2016/11/29/thompson-rubinstein-investment-management-inc-or-maintains-position-in-cvs-health-corporation-cvs.html.

Several research analysts recently weighed in on CVS shares. Mizuho reiterated a “buy” rating and set a $111.00 price target on shares of CVS Health Corporation in a research report on Friday, September 30th. Morgan Stanley reiterated a “hold” rating and set a $104.00 price target on shares of CVS Health Corporation in a research report on Monday, September 12th. Leerink Swann reiterated an “outperform” rating and set a $105.00 price target (down from $110.00) on shares of CVS Health Corporation in a research report on Sunday, October 2nd. Vetr cut CVS Health Corporation from a “strong-buy” rating to a “hold” rating and set a $87.73 price target for the company. in a research report on Thursday, October 6th. Finally, Credit Suisse Group AG reiterated a “buy” rating and set a $115.00 price target on shares of CVS Health Corporation in a research report on Tuesday, September 20th. Five analysts have rated the stock with a hold rating, thirteen have issued a buy rating and one has given a strong buy rating to the stock. CVS Health Corporation has a consensus rating of “Buy” and a consensus target price of $106.24.

CVS Health Corporation Company Profile

CVS Health Corporation, together with its subsidiaries (CVS Health), is a pharmacy company. The Company operates through three business segments: Pharmacy Services, Retail/LTC and Corporate. The Company offers a range of products and services, such as advising patients on their medications at its CVS Pharmacy locations, introducing programs to help control costs for its clients at CVS Caremark, how care is delivered to its patients with conditions through CVS Specialty, pharmacy care for the senior community through Omnicare.

5 Day Chart for NYSE:CVS

Want to see what other hedge funds are holding CVS? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for CVS Health Corporation (NYSE:CVS).

Receive News & Ratings for CVS Health Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for CVS Health Corporation and related companies with MarketBeat.com's FREE daily email newsletter.